AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38433074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led supportive care program for 8 weeks (4 weeks face-to-face, 4 weeks via phone)
Number of subjects: 42
Study 38433074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led supportive care program
Number of subjects: 42
Study 38433074 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 42
Study 38433091 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of breast surgery after NST for patients predicted to have pCR based on MRI and VAB
Number of subjects: 0
Study 38433091 — intervention group
Group type: COMPARATOR
Intervention: Previous studies where patients with pCR underwent breast surgery
Number of subjects: 0
Study 38433125 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX1 (Dexamethasone on day 1)
Number of subjects: 76
Study 38433125 — intervention group
Group type: COMPARATOR
Intervention: DEX4 (Dexamethasone on days 1-4)
Number of subjects: 76
Study 38433191 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (200 µg/ml) and LMWH (5 IU/ml)
Number of subjects: 41
Study 38433191 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study 38433424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride
Number of subjects: 57
Study 38433714 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) models
Number of subjects: 51
Study 38433714 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing (RNA-seq) profiling
Number of subjects: 51
Study 38433714 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing (single-cell RNA-seq)
Number of subjects: 51
Study 38433714 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 51
Study 38433714 — intervention group
Group type: EXPERIMENTAL
Intervention: PDX-derived organoids (PDXO) and patient-derived organoids (PDO)
Number of subjects: 51
Study 38433714 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical models
Number of subjects: 51
Study 38433842 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine (5 micrograms, administered intramuscularly at day 84 and day 140)
Number of subjects: 18
Study 38433842 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 vaccine
Number of subjects: 18
Study 38433842 — intervention group
Group type: COMPARATOR
Intervention: Control (standard TB treatment only)
Number of subjects: 18
Study 38433888 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus etoposide and platinum
Number of subjects: 0
Study 38433888 — intervention group
Group type: COMPARATOR
Intervention: Etoposide and platinum
Number of subjects: 0
Study 38434590 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal home mindfulness practice
Number of subjects: 21
Study 38434590 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal home mindfulness practice
Number of subjects: 21
Study 38434594 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing
Number of subjects: 149
Study 38434594 — intervention group
Group type: COMPARATOR
Intervention: Measure of Immigration and Acculturation Stressors (MIAS)
Number of subjects: 149
Study 38434594 — intervention group
Group type: COMPARATOR
Intervention: Measure of Drinking in Response to Immigration and Acculturation Stressors (MDRIAS)
Number of subjects: 149
Study 38434639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (Lf) in oral nutritional supplements (ONS)
Number of subjects: 75
Study 38434639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 38434698 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Mangostin hydrogel film
Number of subjects: 0
Study 38434698 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38434770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 48
Study 38434770 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 48
Study 38435072 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-CDS intervention
Number of subjects: 6420
Study 38435072 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6420
Study 38435286 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line brigatinib followed by lorlatinib
Number of subjects: 0
Study 38435286 — intervention group
Group type: COMPARATOR
Intervention: Second-line brigatinib followed by lorlatinib
Number of subjects: 0
Study 38435429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy Integrated Community Care (PICC) program - a structured, four-session group-based program guided by experienced pharmacists focusing on medication adherence and diabetes management.
Number of subjects: 94
Study 38435429 — intervention group
Group type: COMPARATOR
Intervention: Standard Diabetes Mellitus Adherence Clinic program (Control group).
Number of subjects: 94
Study 38435809 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (sevoflurane-dexmedetomidine with continuous infusion of lidocaine and ketamine)
Number of subjects: 172
Study 38435809 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (sevoflurane-remifentanil with morphine transition)
Number of subjects: 172
Study 38435944 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hyperamylasemia (POH) defined as serum amylase >100 U/L on postoperative day 1 (POD1)
Number of subjects: 140
Study 38435944 — intervention group
Group type: COMPARATOR
Intervention: Patients without postoperative hyperamylasemia (POH)
Number of subjects: 140
Study 38435944 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hyperamylasemia (POH)
Number of subjects: 140
Study 38435944 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss >350 mL, pancreatic duct size <3 mm, elevated POD1 serum amylase >100 U/L
Number of subjects: 140
Study 38435978 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based EMDR intervention (up to 12 sessions, delivered twice weekly)
Number of subjects: 42
Study 38435978 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study 38435978 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based EMDR intervention
Number of subjects: 42
Study 38436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function (LnRHI)
Number of subjects: 214
Study 38436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (CIMT)
Number of subjects: 214
Study 38436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular stiffness (cfPWV)
Number of subjects: 214
Study 38436075 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 2635
Study 38436075 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 2635
Study 38436075 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide and Furosemide
Number of subjects: 2635
Study 38436174 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 75
Study 38436174 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 75
Study 38436174 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 75
Study 38436365 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin
Number of subjects: 0
Study 38436365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38436463 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg once a day for 14 days
Number of subjects: 63
Study 38436463 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 400 mg twice a day for 14 days
Number of subjects: 63
Study 38436463 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 800 mg twice a day for 14 days
Number of subjects: 63
Study 38436463 — intervention group
Group type: EXPERIMENTAL
Intervention: Delpazolid 1200 mg once a day for 14 days
Number of subjects: 63
Study 38436495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (2.7 mg)
Number of subjects: 0
Study 38436495 — intervention group
Group type: COMPARATOR
Intervention: Intranasal naloxone (4 mg)
Number of subjects: 0
Study 38436589 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples analyzed for lactate dehydrogenase, immunoglobulin E, interleukins, thymus and activation-regulated chemokine, and lymphocyte subpopulations.
Number of subjects: 120
Study 38436589 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital spatial profiling and single-cell RNA sequencing of the lymphoma microenvironment.
Number of subjects: 120
Study 38436589 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological sampling and analysis of skin barrier function.
Number of subjects: 120
Study 38436589 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of life quality parameters.
Number of subjects: 120
Study 38436589 — intervention group
Group type: COMPARATOR
Intervention: Control group of 20 healthy volunteers.
Number of subjects: 120
Study 38436824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic whole-body PET acquisition protocol
Number of subjects: 8
Study 38436921 — intervention group
Group type: EXPERIMENTAL
Intervention: DAAs (sofosbuvir/velpatasvir)
Number of subjects: 84
Study 38436921 — intervention group
Group type: COMPARATOR
Intervention: Postponed DAAs
Number of subjects: 84
Study 38436924 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-strength dual-action tablets (RS-DAT) - niraparib 200 mg/AA 1000 mg once daily
Number of subjects: 0
Study 38436924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-strength dual-action tablets (LS-DAT) - niraparib 100 mg/AA 500 mg
Number of subjects: 0
Study 38436924 — intervention group
Group type: COMPARATOR
Intervention: Single-agent combination (SAC) - abiraterone acetate alone
Number of subjects: 0
Study 38436944 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE (digital therapist-guided prolonged exposure programme)
Number of subjects: 0
Study 38436947 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) 38% concentration solution
Number of subjects: 7418
Study 38436947 — intervention group
Group type: COMPARATOR
Intervention: Sealants with Atraumatic Restorative Treatment (ART)
Number of subjects: 7418
Study 38436998 — intervention group
Group type: EXPERIMENTAL
Intervention: Batoclimab (680 mg, subcutaneous injections, 6 weekly doses)
Number of subjects: 132
Study 38436998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, 6 weekly doses)
Number of subjects: 132
Study 38436998 — intervention group
Group type: EXPERIMENTAL
Intervention: Batoclimab
Number of subjects: 132
Study 38436998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 38437013 — intervention group
Group type: EXPERIMENTAL
Intervention: Empower@Home (wCBT)
Number of subjects: 70
Study 38437013 — intervention group
Group type: COMPARATOR
Intervention: Attention control (friendly phone calls and depressive symptom monitoring)
Number of subjects: 70
Study 38437204 — intervention group
Group type: EXPERIMENTAL
Intervention: Managerial position
Number of subjects: 704
Study 38437204 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 704
Study 38437204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional and longitudinal analysis
Number of subjects: 704
Study 38437238 — intervention group
Group type: EXPERIMENTAL
Intervention: Yathu Yathu (community-based, peer-led sexual and reproductive health services)
Number of subjects: 10974
Study 38437238 — intervention group
Group type: EXPERIMENTAL
Intervention: Yathu Yathu
Number of subjects: 10974
Study 38437238 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10974
Study 38437633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated training programme to implement 10 quality of care measures to reduce LOS with an implementation phase of eight weeks.
Number of subjects: 1829
Study 38437633 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1829
Study 38437633 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 1829
Study 38437725 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CD28 in combination with glofitamab
Number of subjects: 0
Study 38437725 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of glofitamab with CD19-CD28 and CD19-4-1BBL
Number of subjects: 0
Study 38437857 — intervention group
Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec (2×10^13 vg/kg)
Number of subjects: 54
Study 38437868 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the risk A allele (AA)
Number of subjects: 865
Study 38437868 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture activation of aldosterone
Number of subjects: 865
Study 38437868 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of aldosterone
Number of subjects: 865
Study 38437868 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian females under 50 years with AA genotype
Number of subjects: 865
Study 38437868 — intervention group
Group type: COMPARATOR
Intervention: African cohort
Number of subjects: 865
Study 38437873 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-BA (Extended Reality-Enhanced Behavioral Activation)
Number of subjects: 26
Study 38437873 — intervention group
Group type: COMPARATOR
Intervention: Traditional BA (Behavioral Activation)
Number of subjects: 26
Study 38437926 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person + app group (n = 8)
Number of subjects: 22
Study 38437926 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual + app group (n = 7)
Number of subjects: 22
Study 38437926 — intervention group
Group type: COMPARATOR
Intervention: Wait-list, education-enhanced control group (n = 8)
Number of subjects: 22
Study 38437926 — intervention group
Group type: EXPERIMENTAL
Intervention: All app participants
Number of subjects: 22
Study 38437953 — intervention group
Group type: EXPERIMENTAL
Intervention: T-TEER (tricuspid transcatheter edge-to-edge repair)
Number of subjects: 186
Study 38437986 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (TG)
Number of subjects: 50
Study 38437986 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face group (FFG)
Number of subjects: 50
Study 38437999 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time computer-aided detection (CADe)
Number of subjects: 1100
Study 38437999 — intervention group
Group type: COMPARATOR
Intervention: Traditional colonoscopy
Number of subjects: 1100
Study 38438123 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S full-dose regimen (2 full doses at months 0 and 1)
Number of subjects: 1500
Study 38438123 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S fractional-dose regimen (one-fifth doses)
Number of subjects: 1500
Study 38438123 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S full-dose regimen (R012-14-26)
Number of subjects: 1500
Study 38438123 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S fractional-dose regimen (Fx012-14-26)
Number of subjects: 1500
Study 38438123 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S fractional-dose regimen (Fx017-20-32)
Number of subjects: 1500
Study 38438123 — intervention group
Group type: COMPARATOR
Intervention: Rabies control vaccine
Number of subjects: 1500
Study 38438427 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine candidate (40 μg, two doses administered 28 days apart)
Number of subjects: 0
Study 38438427 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 vaccine (30 μg, two doses administered 21 days apart)
Number of subjects: 0
Study 38438427 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine candidate
Number of subjects: 0
Study 38438427 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 vaccine
Number of subjects: 0
Study 38438576 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist led behaviour change intervention (4 sessions in 8 weeks)
Number of subjects: 25
Study 38438576 — intervention group
Group type: COMPARATOR
Intervention: Control group (PA information leaflet only)
Number of subjects: 25
Study 38438576 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study design and intervention
Number of subjects: 25
Study 38438576 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist led behaviour change intervention
Number of subjects: 25
Study 38438576 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care professionals and patient participants feedback
Number of subjects: 25
Study 38438681 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 mg bupivacaine
Number of subjects: 42
Study 38438681 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 mg bupivacaine
Number of subjects: 42
Study 38438681 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg bupivacaine
Number of subjects: 42
Study 38438681 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.75 mg bupivacaine
Number of subjects: 42
Study 38438707 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 936
Study 38438735 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet arm (sintilimab, chidamide, and bevacizumab)
Number of subjects: 48
Study 38438735 — intervention group
Group type: COMPARATOR
Intervention: Doublet arm (sintilimab and chidamide)
Number of subjects: 48
Study 38438735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 48
Study 38438843 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration in home care
Number of subjects: 20
Study 38438843 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration in steady care situations
Number of subjects: 20
Study 38438843 — intervention group
Group type: EXPERIMENTAL
Intervention: Means of communication (telephone, fax, e-mail)
Number of subjects: 20
Study 38438843 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal acquaintance and mutual trust
Number of subjects: 20
Study 38438843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of mutual availability, limited time, and inadequate compensation
Number of subjects: 20
Study 38438843 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint collaborations
Number of subjects: 20
Study 38438843 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexity of healthcare situation
Number of subjects: 20
Study 38438859 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-based preventive intervention including functional examination and lifestyle counselling
Number of subjects: 27
Study 38438859 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional examination consisting of 20 established tests and a sub-maximal ergometer test
Number of subjects: 27
Study 38438859 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk profile based on functional examination
Number of subjects: 27
Study 38438859 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional screening and lifestyle counselling
Number of subjects: 27
Study 38438923 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg roflumilast
Number of subjects: 0
Study 38438923 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg roflumilast
Number of subjects: 0
Study 38438923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38438945 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parental involvement in PA
Number of subjects: 425
Study 38438945 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parental support for PA
Number of subjects: 425
Study 38438945 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall parental practices (involvement in PA + support for PA + control of screen viewing context)
Number of subjects: 425
Study 38438945 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall parental practices
Number of subjects: 425
Study 38438945 — intervention group
Group type: COMPARATOR
Intervention: Parental control of screen viewing contexts and neighbourhood environmental factors
Number of subjects: 425
Study 38439024 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC)
Number of subjects: 0
Study 38439024 — intervention group
Group type: COMPARATOR
Intervention: Time-based cord clamping (TBCC)
Number of subjects: 0
Study 38439027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.1~1.0 μg/kg/h for 24 h
Number of subjects: 368
Study 38439027 — intervention group
Group type: COMPARATOR
Intervention: Saline (control) for 24 h
Number of subjects: 368
Study 38439027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 368
Study 38439027 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 368
Study 38439069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index software
Number of subjects: 485
Study 38439076 — intervention group
Group type: EXPERIMENTAL
Intervention: ROAD Home implementation strategy
Number of subjects: 40
Study 38439076 — intervention group
Group type: COMPARATOR
Intervention: Stewardship as usual control
Number of subjects: 40
Study 38439079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 505
Study 38439079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib + Fulvestrant
Number of subjects: 505
Study 38439079 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 505
Study 38439092 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Schema Therapy (GST)
Number of subjects: 232
Study 38439092 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy Enhanced (CBT-E)
Number of subjects: 232
Study 38439113 — intervention group
Group type: EXPERIMENTAL
Intervention: Expect With Me group prenatal care
Number of subjects: 41
Study 38439582 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 tertile 3
Number of subjects: 1111
Study 38439582 — intervention group
Group type: COMPARATOR
Intervention: CA-125 tertile 1
Number of subjects: 1111
Study 38439582 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper CA-125 tertile
Number of subjects: 1111
Study 38439582 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1111
Study 38439783 — intervention group
Group type: EXPERIMENTAL
Intervention: Onchocerciasis-associated epilepsy (OAE) cases (n=20)
Number of subjects: 40